Vimarsana
Biggest News Aggregation in the World

Page 3 - Iobt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Iobt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Iobt Today - Breaking & Trending Today

IO Biotech (NASDAQ:IOBT) Price Target Raised to $11.00 - Vimarsana News

IO Biotech (NASDAQ:IOBT) Price Target Raised to $11.00

IO Biotech (NASDAQ:IOBT – Get Rating) had its target price hoisted by analysts at HC Wainwright from $10.00 to $11.00 in a research report issued on Friday, The Fly reports. HC Wainwright’s price target would indicate a potential upside of 431.35% from the stock’s previous close. Separately, Morgan Stanley reduced their price objective on shares […]

Source: wkrb13.com
Financial Contrast: IO Biotech (IOBT) and Its Competitors - Vimarsana News

Financial Contrast: IO Biotech (IOBT) and Its Competitors

IO Biotech (NASDAQ:IOBT – Get Rating) is one of 994 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare IO Biotech to similar businesses based on the strength of its risk, analyst recommendations, earnings, dividends, valuation, institutional ownership and profitability. Volatility & Risk IO Biotech has […]

Source: wkrb13.com
IO Biotech, Inc. (NASDAQ:IOBT) Sees Significant Decline in Short Interest - Vimarsana News

IO Biotech, Inc. (NASDAQ:IOBT) Sees Significant Decline in Short Interest

IO Biotech, Inc. (NASDAQ:IOBT – Get Rating) saw a significant drop in short interest in May. As of May 31st, there was short interest totalling 2,900 shares, a drop of 44.2% from the May 15th total of 5,200 shares. Based on an average trading volume of 53,200 shares, the short-interest ratio is currently 0.1 days. […]

IO Biotech (NASDAQ:IOBT) Downgraded by Zacks Investment Research to "Hold" - Vimarsana News

IO Biotech (NASDAQ:IOBT) Downgraded by Zacks Investment Research to "Hold"

IO Biotech (NASDAQ:IOBT – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday, Zacks.com reports. According to Zacks, “IO Biotech Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel, immune-modulating cancer therapies based on its T-win(R) technology platform. IO […]

Jefferies Financial Group Weighs in on IO Biotech, Inc.'s Q2 2022 Earnings (NASDAQ:IOBT) - Vimarsana News

Jefferies Financial Group Weighs in on IO Biotech, Inc.'s Q2 2022 Earnings (NASDAQ:IOBT)

IO Biotech, Inc. (NASDAQ:IOBT – Get Rating) – Equities researchers at Jefferies Financial Group raised their Q2 2022 earnings estimates for shares of IO Biotech in a report issued on Monday, May 16th. Jefferies Financial Group analyst C. Howerton now forecasts that the company will post earnings per share of ($0.40) for the quarter, up […]